Retatrutide is frequently discussed in scientific literature as a triple receptor agonist model because it is studied across GLP-1, GIP, and glucagon receptor pathways
Its triage table describes IV fluids, glucose monitoring, an electrolyte panel and symptomatic care as the response to severe vomiting, dehydration, dizziness or hypoglycemia
Junjie Zhou, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Evidence from a multicenter, long-term cardiovascular outcome trial demonstrated that GLP-1RAs reduce mortality associated with cardiovascular disease and confer protective effects by decreasing the incidence of myocardial infarction and nonfatal stroke
It's not listed as available through major third-party retailers at the time of this publication